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The special challenge for a successful HIV vaccine is due to
HIV DNA integration, HIV variation, and its early harm to
the immune system. Though easy to describe, the chal-
lenge is uniquely difficult compared to past successful vac-
cines. However, most if not all current and past vaccine
candidates have not taken these features of HIV into
account. What is needed and has been needed for over
two decades are: (1) far more availability of primates and
to a broader number of scientists; (2) an immune
response which is sustained; (3) an immune response
which is broad and results in sterilizing immunity or close
to sterilizing immunity. The key, of course, is finding the
right immunogen.
At IHV we (with G. Lewis, A. DeVico) and our collaborator
at Profectus BioSciences, Inc. (T. Fouts and J. Eldridge)
and at Advanced BioScience Laboratories (R. Pal) have
focused our attention on a complex of gp120 and the
region of CD4 (DID2) binding to gp120. Chiefly, this has
been by expression of a full length single chain (FLSC) of
gp120 (Bal) and human or rhesus DID2 separated by a
run of sequences encoding 20 neutral amino acids. The
goal was to make a fixed transitional state form of gp120
which exposes surface portions that interact with CCR5.
These CCR5 binding regions are originally hidden both by
their interior location in gp120 and by carbohydrate.
These regions are conserved and functionally required for
CCR5 binding. Consequently, the hypothesis is that
epitopes derived from this region, referred to as CD4
induced epitopes (CD4i) may stimulate broad neutraliz-
ing antibodies.
In vitro studies of antibodies induced in uninfected small
animals supported this concept. This was followed by
three challenge studies in rhesus macaques using a
SHIV162p3 challenge and vaccinating with protein
derived from FLSC expressed in 293 human cells and with
rhesus CD4 sequences. The results showed no sterilizing
immunity but ultimate protection against this heterolo-
gous challenge. Protection correlated with CD4i antibod-
ies but not with antibodies to gp120 (alone), soluble
CD4, or conventional neutralizing antibody activity. We
propose that these antibodies may have acted by ADCC
activity rather than by interfering with HIV cell entry.
Other studies showed that protein derived from FLSC
expressed in CHO cells did not provide protection sug-
gesting that different glycosylation forms of gp120 may
yield gp120/CD4 complexes with different forms.
Further studies are in progress to verify ADCC activity, to
increase the titer and sustainability of these CD4i antibod-
ies and to verify their role in this candidate vaccine by
using monoclonal CD4i antibodies in passive immuniza-
tion.
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